Moderna rose 4% in early premarket trade as it said late Tuesday that early-stage data suggests its COVID-19 vaccine can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults. The study was published in The New England Journal of Medicine. Moderna’s stock has surged 251% this year.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.